

**CAPT Amanda Cohn**  
**National Center for Immunization and Respiratory Diseases**  
**Centers for Disease Control and Prevention**  
**1600 Clifton Rd, Atlanta, GA 30333 MS C-09**  
**Telephone: (404) 639-6039**  
**E-mail: [acohn@cdc.gov](mailto:acohn@cdc.gov)**

**CURRENT POSITION**

Chief Medical Officer (Acting), Office of Vaccine Policy, Preparedness, and Global Health,  
Office of the Director, NCIRD  
Executive Secretary, Advisory Committee on Immunization Practices (ACIP)

**EDUCATION**

2001 M.D. Emory University School of Medicine, Atlanta, GA  
1997 B.A. (English) Brown University, Providence, RI (with honors)

**POSTGRADUATE TRAINING**

2004 – 2006 Epidemic Intelligence Service, CDC, Atlanta, GA  
2001 – 2004 Residency and Internship, Boston Combined Residency in  
Pediatrics, Boston, MA

**PROFESSIONAL LICENSURE AND BOARD CERTIFICATION**

2004-present Board Certified, Pediatrics (Valid through 12/21)  
2004-present Georgia State Medical License #59671 (valid through January 31, 2021)

**FACULTY and CLINICAL APPOINTMENTS**

2006-2012 St. Joseph's Hospital, MercyCare Clinic

**WORK EXPERIENCE**

3/2019-present **Chief Medical Officer (Acting), Vaccine Policy, Preparedness, and  
Global Health, Office of the Director, NCIRD, CDC**

11/2015-present **Executive Secretary, ACIP and Senior Advisor, Vaccines  
Office of the Director, NCIRD, CDC**

5/2014-11/2015 **Deputy Division Director, Immunization Services Division, NCIRD,  
CDC**

01/2013-05/2014      **Acting Epidemiology Team Lead**  
**Meningitis and Vaccine Preventable Diseases, DBD, NCIRD, OD**

06/2006-12/2012      **Medical Officer, Epidemiology Team**  
**Meningitis and Vaccine Preventable Diseases, Division of Bacterial**  
**Disease, NCIRD, CDC**

07/2004-06/2006      **Epidemic Intelligence Service (EIS) Officer,**  
**Epidemiology Program Office**  
**Centers for Disease Control and Prevention, Atlanta, GA**  
**Assigned to: Bacterial Vaccine Preventable Diseases Branch, National**  
**Immunization Program**

## **DEPLOYMENTS**

Atlanta              Incidence Manager, US Measles Outbreak (NCIRD), 2019

Atlanta              Team lead for Epidemiology Team for Zika Emergency Operations Center, March-April, 2016.

Sierra Leone        Team lead for the Sierra Leone Trial to Introduce a Vaccine for Ebola (STRIVE), November 2015.

Sierra Leone        Team lead for the Sierra Leone Trial to Introduce a Vaccine for Ebola (STRIVE), October-November 2014.

Atlanta              Team lead for the Vaccines Task Force, Emergency Operations Center, September-October, 2014.

Atlanta              Vaccines Task Force lead, Unaccompanied Minors Response, Emergency Operations Center, June-August 2014.

Atlanta              Lead for H1N1 Vaccine Effectiveness evaluation, September 2009-January 2010.

Jackson, MS        Hurricane Katrina Response, 2006.

## **PROFESSIONAL MEMBERSHIPS**

2007 to present  
2004 to present

Member of Commissioned Officers Association  
American Academy of Pediatrics

## **PUBLICATIONS**

### ***Peer Reviewed Journals***

1. Pike J, Leidner AJ, MacNeil JR, **Cohn AC**. [Review of the economic evidence presented to the United States Advisory Committee on Immunization Practices, 2012-2016.](#) *Vaccine*. 2019 Jan 3;37(1):7-10. doi: 10.1016/j.vaccine.2018.11.055
2. Meissner HC, Farizo K, Pratt D, Pickering LK, **Cohn AC**. [Understanding FDA-Approved Labeling and CDC Recommendations for Use of Vaccines.](#) *Pediatrics*. 2018 Sep;142(3).
3. Mbaeyi SA, Blain A, Whaley MJ, Wang X, **Cohn AC**, MacNeil JR. [Epidemiology of Meningococcal Disease Outbreaks in the United States, 2009-2013.](#) *Clin Infect Dis*. 2019 Feb 1;68(4):580-585
4. McNamara LA, MacNeil JR, **Cohn AC**, Stephens DS. [Mass chemoprophylaxis for control of outbreaks of meningococcal disease.](#) *Lancet Infect Dis*. 2018 Sep;18(9):e272-e281.
5. MacNeil JR, Blain AE, Wang X, **Cohn AC**. [Current Epidemiology and Trends in Meningococcal Disease-United States, 1996-2015.](#) *Clin Infect Dis*. 2018 Apr 3;66(8):1276-1281.
6. Lutz CS, Carr W, Cohn A, Rodriguez L. [Understanding barriers and predictors of maternal immunization: Identifying gaps through an exploratory literature review.](#) *Vaccine*. 2018 Nov 26;36(49):7445-7455.
7. Carter RJ, Idriss A, Widdowson MA, Samai M, Schrag SJ, Legardy-Williams JK, Estivariz CF, Callis A, Carr W, Webber W, Fischer ME, Hadler S, Sahr F, Thompson M, Greby SM, Edem-Hotah J, Momoh RM, McDonald W, Gee JM, Kallon AF, Spencer-Walters D, Bresee JS, Cohn A, Hersey S, Gibson L, Schuchat A, Seward JF. [Implementing a Multisite Clinical Trial in the Midst of an Ebola Outbreak: Lessons Learned From the Sierra Leone Trial to Introduce a Vaccine Against Ebola.](#)
8. **AC Cohn**, JR MacNeil, LH Harrison, R Lynfield, A Reingold, W Schaffner, et al. Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine. *Pediatrics*, e20162193; 2017
9. Tomczyk S, Arriola CS, Beall B, Benitez A, Benoit SR, Berman L, Bresee J, da Gloria Carvalho M, Cohn A, Cross K, Diaz MH, Francois Watkins LK, Gierke R, Hagan JE, Harris AM, Jain S, Kim L, Kobayashi M, Lindstrom S, McGee L, McMorrow M, Metcalf BL, Moore MR, Moura I, Nix WA, Nyangoma E, Oberste MS, Olsen SJ, Pimenta F, Socias C, Thurman K, Waller J, Waterman SH, Westercamp M, Wharton M, Whitney CG, Winchell

JM, Wolff B, Kim C. [Multistate Outbreak of Respiratory Infections Among Unaccompanied Children, June 2014-July 2014.](#) Clin Infect Dis. 2016 Jul 1;63(1):48-56.

10. K Russell, SL Hills, AM Oster, CC Porse, G Danyluk, M Cone, R Brooks, S Scotland, E Schiffman, C Fredette, JL White, K Ellingson, A Hubbard, **A Cohn**, M Fischer, P Mead, AM Powers, JT Brooks. Male-to-Female Sexual Transmission of Zika Virus- United States, January-April 2016. Clin Infect Dis (2016) 64 (2): 211-213.
11. Breakwell, L, Vogt, T, Fleming, DFerris, M, Briere, E, **Cohn, A**, Liang, J. Understanding Factors Affecting University A Students' Decision to Receive an Unlicensed Serogroup B Meningococcal Vaccine. Journal of Adolescent Health. 2016; 59(4); 457-464.
12. CM Harris, HM Wu, J Li, HI Hall, A Lee, E Zell, LH Harrison, S Petit, **AC Cohn**. Meningococcal Disease in Patients With Human Immunodeficiency Virus Infection: A Review of Cases Reported Through Active Surveillance in the United States, 2000-2009. Open Forum Infectious Diseases 3 (4), 2016.
13. AE Blain, S Mandal, H Wu, JR MacNeil, LH Harrison, MM Farley, **AC Cohn**., Penicillin Use in Meningococcal Disease Management: Active Bacterial Core Surveillance Sites, 2009. Open Forum Infectious Diseases 3 (3), 2016.
14. Faulkner, TH Skoff, ML Tondella, **A Cohn**, TA Clark, SW Martin. Trends in pertussis diagnostic testing in the United States, 1990 to 2012AE The Pediatric infectious disease journal 35 (1), 39-44; 2016.
15. **A Cohn**, J MacNeil. The changing epidemiology of meningococcal disease. Infectious disease clinics of North America 29 (4), 667-677; 2015.
16. BH Harcourt, RD Anderson, HM Wu, **AC Cohn**, JR MacNeil, TH Taylor, et al. Population-based surveillance of Neisseria meningitidis antimicrobial resistance in the United States. Open forum infectious diseases 2 (3), 2015.
17. LA McNamara, AM Shumate, P Johnsen, JR MacNeil, M Patel, T Bhavsar, **AC Cohn**... First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics 135 (5), 798-804; 2015.
18. X Wang, KA Shutt, JT Vuong, **A Cohn**, J MacNeil, S Schmink, B Plikaytis, et al. Changes in the population structure of invasive Neisseria Meningitidis in the United States after quadrivalent meningococcal conjugate vaccine licensure. Journal of Infectious Diseases 211(12), 1887-1894; 2015.
19. SA Meyer, JL Kambou, **A Cohn**, JL Goodson, B Flannery, I Medah.... Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso—Implications for introduction of PsA-TT into the Expanded Programme on Immunization. Vaccine 33 (12), 1492-1498; 2015.

20. JR MacNeil, N Bennett, MM Farley, LH Harrison, R Lynfield, M Nichols...**AC Cohn**. Epidemiology of infant meningococcal disease in the United States, 2006-2012. *Pediatrics* 135 (2), e305-e31; 2015.
21. S Meyer, J Macneil, A Blain, **A Cohn**. Epidemiology of Serogroup B Meningococcal Outbreaks and Interim Guidelines for the Use of an Unlicensed Serogroup B Vaccine Under a CDC-Sponsored IND for the Control of Outbreaks in Organizational Settings. *Open Forum Infectious Diseases* 1 (suppl 1), S35-S36, 2014.
22. A Blain, J MacNeil, X Wang, N Bennett, MM Farley, LH Harrison, C Lexa..., **A Cohn**. Invasive *Haemophilus influenzae* disease in adults  $\geq$  65 years, United States, 2011. *Open forum infectious diseases*.
23. M Patel, S Romero-Steiner, MP Broderick, CG Thomas, BD Plikaytis, **AC Cohn** et al. Persistence of serogroup C antibody responses following quadrivalent meningococcal conjugate vaccination in United States military personnel. *Vaccine* 32 (30), 3805-3809.
24. JS Bradley, G Peacock, SE Krug, WA Bower, **AC Cohn**, et al. Pediatric anthrax clinical management. *Pediatrics*, 0563; 2014.
25. MacNeil JR, Medah I, Koussoubé D, Novak RT, **Cohn AC**, 16 Diomandé FVK, et al. Serogroup W meningitis, Burkina Faso, 2012. *Emerg Infect Dis*. 17 2014 Mar
26. Patel, M, **Cohn, AC**, Carlone, G et al. Persistence of Serogroup C Antibody Responses Following Quadrivalent Meningococcal Conjugate Vaccination in United States Military Personnel. *Vaccine* (in press)
27. Medah, I, Yelbaogo, D, Kambou, JL, Wannemuehler, K, Goodson, JL, Flannery, B, Cohn, A et al. Serogroup A Meningococcal Conjugate Vaccine Coverage After the First National Mass Immunization Campaign-Burkina Faso, 2011 (vol 50, pg 1022, 2012), *Journal of the American Medical Association*. 309.11 (2013): 1104-1106.
28. Wiringa AE, Shutt KA, Marsh JW, **Cohn AC**, Messonnier NE, Zansky SM, et al. Geotemporal Analysis of *Neisseria meningitidis* Clones in the United States: 2000-2005. *PLoS One*. 2013 Dec 12;8(12):e8204
29. Tartof S, **Cohn A**, Tarbangdo F, Djingarey MH, Messonnier N, Clark TA, et al. Identifying optimal vaccination strategies for serogroup A *Neisseria meningitidis* conjugate vaccine in the African meningitis belt. *PLoS One*. 2013 May 9;8(5):e63605
30. Mandal S, Wu HM, MacNeil JR, Machesky K, Garcia J, Plikaytis BD, Quinn K, King L, Schmink SE, Wang X, Mayer LW, Clark TA, Gaskell JR, Messonnier NE, DiOrio M, **Cohn AC**. Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States. *CID*.2013; Aug;57(3):344-348.

31. Rodgers L, Martin SW, **Cohn A**, et al. Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating *Bordetella holmesii* and *Bordetella pertussis*--Ohio, 2010-2011. *Clin Infect Dis*. 2013 Feb;56(3):322-31
32. Terranella A, Beekmann SE, Polgreen PM, **Cohn A**, Wu HM, Clark TA. Practice patterns of infectious disease physicians for management of meningococcal disease. *The Pediatric infectious disease journal*. Nov 2012;31(11):e208-212.
33. Skoff TH, **Cohn AC**, Clark TA, Messonnier NE, Martin SW. Early Impact of the US Tdap vaccination program on pertussis trends. *Archives of pediatrics & adolescent medicine*. Apr 2012;166(4):344-349.
34. Santibanez TA, Shefer A, Briere EC, **Cohn AC**, Groom AV. Effects of a nationwide Hib vaccine shortage on vaccination coverage in the United States. *Vaccine*. Jan 20 2012;30(5):941-947.
35. Mandal S, Tatti KM, Woods-Stout D, **Cohn A**, et al. Pertussis Pseudo-outbreak linked to specimens contaminated by *Bordetella pertussis* DNA From clinic surfaces. *Pediatrics*. Feb 2012;129(2):e424-430.
36. Lowther SA, Shinoda N, Juni BA, **Cohn, AC** et al. Haemophilus influenzae type b infection, vaccination, and H. influenzae carriage in children in Minnesota, 2008-2009. *Epidemiology and infection*. Mar 2012;140(3):566-574.
37. Livorsi DJ, Macneil JR, **Cohn AC**, et al. Invasive Haemophilus influenzae in the United States, 1999-2008: Epidemiology and outcomes. *The Journal of infection*. Dec 2012;65(6):496-504.
38. Jackson ML, Rose CE, **Cohn A**, et al. Modeling insights into Haemophilus influenzae type b disease, transmission, and vaccine programs. *Emerging infectious diseases*. Jan 2012;18(1):13-20.
39. Briere EC, Jackson M, Shah SG, **Cohn, AC** et al. Haemophilus influenzae type b disease and vaccine booster dose deferral, United States, 1998-2009. *Pediatrics*. Sep 2012;130(3):414-420.
40. Anderson R, Wang X, Briere EC, **Cohn, AC** et al. Haemophilus haemolyticus isolates causing clinical disease. *Journal of clinical microbiology*. Jul 2012;50(7):2462-2465.
41. **Cohn AC**, Harrison LH. Meningococcal vaccines: current issues and future strategies. *Drugs*. 2013 Jul;73(11):1147-55.
42. **Cohn AC**, Messonnier NE. Inching toward a serogroup B meningococcal vaccine for infants. *JAMA : the journal of the American Medical Association*. Feb 8 2012;307(6):614-615.

43. Wang X, Mair R, Hatcher C, **Cohn, AC** et al. Detection of bacterial pathogens in Mongolia meningitis surveillance with a new real-time PCR assay to detect Haemophilus influenzae. *International journal of medical microbiology : IJMM*. Apr 2011;301(4):303-309.
44. Wang X, **Cohn A**, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. *Vaccine*. Jun 24 2011;29(29-30):4739-4744.
45. Thomas JD, Jackson ML, Sharma D, **Cohn, AC** et al. Haemophilus influenzae type b carriage among young children in metropolitan Atlanta in the context of vaccine shortage and booster dose deferral. *Clinical and vaccine immunology : CVI*. Dec 2011;18(12):2178-2180.
46. Stokley S, **Cohn A**, Jain N, McCauley MM. Compliance with recommendations and opportunities for vaccination at ages 11 to 12 years: evaluation of the 2009 national immunization survey-teen. *Archives of pediatrics & adolescent medicine*. Sep 2011;165(9):813-818.
47. Terrenella, A, **Cohn, A**, and Clark, T. Meningococcal Conjugate Vaccines: Optimizing Global Impact. *Inf and Drug Res*. Sept 2011.
48. Macneil JR, **Cohn AC**, Zell ER, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. *The Pediatric infectious disease journal*. Jun 2011;30(6):451-455.
49. MacNeil JR, **Cohn AC**, Farley M, et al. Current epidemiology and trends in invasive Haemophilus influenzae disease--United States, 1989-2008. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. Dec 2011;53(12):1230-1236.
50. Macneil, J, Thomas, J and **Cohn, A**. Meningococcal Meningitis: Shifting Epidemiology and Genetic Mechanisms That May Contribute to Serogroup C Virulence. *Curr Inf Dis Rep*. 2011. Volume 13, Number 4, 374-379
51. Allison MA, **Cohn AC**, Stokley S, et al. Timing of adolescent meningococcal conjugate vaccination attitudes and practices of pediatricians and family medicine physicians. *American journal of preventive medicine*. Dec 2011;41(6):581-587.
52. Lu PJ, Jain N, **Cohn AC**. Meningococcal conjugate vaccination among adolescents aged 13-17 years, United States, 2007. *Vaccine*. Mar 8 2010;28(11):2350-2355.
53. Jain N, Stokley S, **Cohn A**. Receipt of tetanus-containing vaccinations among adolescents aged 13 to 17 years in the United States: National Immunization Survey-Teen 2007. *Clinical therapeutics*. Aug 2010;32(8):1468-1478.
54. Harrison LH, Shutt KA, Schmink SE, **Cohn, AC** et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate

vaccine era--United States, 2000-2005. *The Journal of infectious diseases*. Apr 15 2010;201(8):1208-1224.

55. **Cohn AC**, MacNeil JR, Harrison LH, et al. Changes in *Neisseria meningitidis* disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. Jan 15 2010;50(2):184-191.
56. Wu HM, Harcourt BH, Hatcher CP, **Cohn, AC** et al. Emergence of ciprofloxacin-resistant *Neisseria meningitidis* in North America. *The New England journal of medicine*. Feb 26 2009;360(9):886-892
57. Broder KR, **Cohn AC**, Schwartz B, et al. Adolescent immunizations and other clinical preventive services: a needle and a hook? *Pediatrics*. Jan 2008;121 Suppl 1:S25-34.
58. **Cohn A**, Broder KR, Pickering LK. Immunizations in the United States: a rite of passage. *Pediatrics Clinics of North America* 2005;52:669-693.
59. **Cooper A**. Yusuf H. Rodewald L. Malik T. Pollard R. Pickering L. Attitudes, practices, and preferences of pediatricians regarding initiation of hepatitis B immunization at birth. *Pediatrics*. 2005;108(6):E98

### **MMWR Publications**

1. Patel M, Lee AD, Redd SB, Clemmons NS, McNall RJ, **Cohn AC**, Gastañaduy PA. [Increase in Measles Cases - United States, January 1-April 26, 2019](#). *MMWR Morb Mortal Wkly Rep*. 2019 May 3;68(17):402-404.
2. Sharoda Dasgupta; Sarah Reagan-Steiner; Dana Goodenough; Kate Russell; Mary Tanner, MD; ...**Amanda Cohn, MD**; Christopher Gregory; The Zika Virus Response Epidemiology and Laboratory Team Patterns in Zika Virus Testing and Infection, by Report of Symptoms and Pregnancy Status — United States, January 3–March 5, 2016. *MMWR*, April 22, 2016 / 65(15);395–399
3. Alexandra M. Oster; Kate Russell; Jo Ellen Stryker; Allison Friedman; Rachel E. Kachur; Emily E. Petersen; Denise J. Jamieson; **Amanda C. Cohn**; John T. Brooks, MD. Update: Interim Guidance for Prevention of Sexual Transmission of Zika Virus — United States, 2016. *MMWR*, April 1, 2016 / 65(12);323–325.
4. Emily E. Petersen; Kara N.D. Polen; Dana Meaney-Delman; Sascha R. Ellington; Titilope Oduyebo; **Amanda Cohn**; Alexandra M. Oster et al. Update: Interim Guidance for Health Care Providers Caring for Women of Reproductive Age with Possible Zika Virus Exposure — United States, 2016. *MMWR*. April 1, 2016 / 65(12);315–322



5. Paige Armstrong; Morgan Hennessey; Monica Adams; Cara Cherry; Sophia Chiu... Zika Virus Response Epidemiology and Laboratory Team Travel-Associated Zika Virus Disease Cases Among U.S. Residents — United States, January 2015–February 2016. *MMWR*. March 25, 2016 / 65(11);286–289
6. JR MacNeil, L Rubin, L McNamara, EC Briere, TA Clark, **AC Cohn**. Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013. *MMWR Morb Mortal Wkly Rep* 63 (24), 527-530; 2014
7. Briere, EC, Rubin, L, Moro, P, **Cohn, A**, Clark, T, Messonnier, N. *Haemophilus Influenzae* Type b Vaccines. *MMWR Rec and Rep*. 2014;63(RR01);1-14.
8. **Cohn, AC**, MacNeil, J, Clark, T, Ortega-Sanchez, I, Briere, E, Meissner, C, Baker, C and Messonnier, N. Prevention and Control of Meningococcal Disease. *MMWR Rec and Rep*. March 22, 2013; 62(RR02);1-22.
9. CDC (lead author). Recommendations from the Advisory Committee on Immunization Practices (ACIP) for Use of Meningococcal Conjugate Vaccines in Infants. *MMWR*, Jan 2013.
10. CDC (lead author). Comparison of Meningococcal Disease Surveillance Systems — United States, 2005–2008. *MMWR*, May 4, 2012 / 61(17);306-308
11. CDC (co-author) Evaluation of Meningitis Surveillance Before Introduction of Serogroup A Meningococcal Conjugate Vaccine — Burkina Faso and Mali. *MMWR*. 2012: 61 (50); 1025-1028.
12. CDC (co-author). Serogroup A Meningococcal Conjugate Vaccine Coverage After the First National Mass Immunization Campaign — Burkina Faso, 2011. *MMWR*. 2012: 61 (50); 1022-1024.
13. Shefer, A, Atkinson, W, Friedman, C, Kahur, DT, Mootrey, G, Bialek, SR, Cohn, A, et al. Immunization of Health-Care Personnel: Recommendations of the Advisory Committee on Immunization Practices. 2011;60 (RR07);1-45.
14. CDC (co-author) National, State, and Local Area Vaccination Coverage among Adolescents Aged 13--17 Years --- United States, 2009. *MMWR*. August 20, 2010 / 59(32);1018-1023
15. CDC (lead author). Updated Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Revaccination of Persons at Prolonged Increased Risk for Meningococcal Disease. *MMWR*. 2009: 58(37);1042-1043.
16. CDC (co-author). Continued Shortage of *Haemophilus influenzae* Type b (Hib) Conjugate Vaccines and Potential Implications for Hib Surveillance --- United States, 2008. *MMWR*. 2008: 57(46);1252-1255

17. CDC (co-author) . Emergence of Fluoroquinolone-Resistant *Neisseria meningitidis* --- Minnesota and North Dakota, 2007—2008. *MMWR*. 2008: 57(07); 173-175.
18. CDC (lead author). Report from the Advisory Committee on Immunization Practices (ACIP): Decision Not to Recommend Routine Vaccination of All Children Aged 2--10 Years with Quadrivalent Meningococcal Conjugate Vaccine (MCV4). *MMWR*. 57(17); 462-465.
19. CDC (lead author). Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MCV4) in Children Aged 2--10 Years at Increased Risk for Invasive Meningococcal Disease. *MMWR*. 2007: 56(48);1265-1266.
20. CDC (lead author). Revised Recommendations of the Advisory Committee on Immunization Practices to Vaccinate all Persons 11-18 years with Meningococcal Conjugate Vaccine. *MMWR*. 2007:56;794-795.
21. Kretsinger, K, Broder, KR, Cortese, M, Joyce, P, Ortega-Sanchez, I, Lee, GM, Tiwari, T, **Cohn, AC**, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines (Tdap): recommendations of the Advisory Committee on Immunization Practices. *Morbidity and Mortality Weekly Report (MMWR)* 2006;55 (RR-17):1-33.
22. Broder, KR, Cortese, MM, Iskander, JK, Kretsinger, K, Slade, B, Brown, K, Mijalski, C, Tiwari, T, Weston, EJ, Cohn, AC et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines (Tdap): recommendations of the Advisory Committee on Immunization Practices. *MMWR* 2006;55(RR03):1-34.
23. CDC (co-author). Pertussis Outbreak in an Amish Community --- Kent County, Delaware, September 2004--February 2005. *MMWR*. 2006:55;817-821.
24. CDC (lead author). Pertussis --- United States, 2001—2003. *MMWR*. 2005:54;1283-1286.
25. CDC (co-author). Mississippi Experience with Surveillance for Illness and Injury After Hurricane Katrina, September 2005. *MMWR*.
26. CDC (lead author). *Vibrio* Illnesses after Hurricane Katrina- Multiple States, August-September, 2005.” *MMWR* 2005;54:928-31.

### ***Book Chapters***

1. **A Cohn**, L Rodewald, W Orenstein, and A Schuchat. The US Immunization Program. In Plotkin, Orenstein, and Offit, ed: *Vaccines*, 7<sup>th</sup> Edition.

2. AJ Pollard, I Feavers, **A Cohn**. Prevention of meningococcal disease through vaccination, In Feavers, Pollard, and Sadarangani, ed. Handbook of Meningococcal Disease Management, 91-103; 2016.
3. **Cohn, AC** and Messonnier, NE. Prevention of Bacterial Meningitis. In MW Scheld, CM Marra, RJ Whitley, ed. *Infections of the Neurologic System*. 2014.
4. **Cohn, AC** and MacNeil, J. Meningococcal Disease. In: Brunette GW, ed: The Yellow Book: CDC Health Information for International Travel 2014. Atlanta: US Department of Health and Human Service. New York: Oxford University Press, 2014
5. MacNeil, J and **Cohn, AC**. In Manual for the Surveillance of Vaccine-Preventable Diseases. CDC. 6<sup>th</sup> Edition, 2013.
6. **Cohn, AC** and Jackson, M. Meningococcal Disease. In: Brunette GW, ed: The Yellow Book: CDC Health Information for International Travel 2012. Atlanta: US Department of Health and Human Service. New York: Oxford University Press, 2012